US Patent

US8404724 — Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor

Method of Use · Assigned to Millennium Pharmaceuticals Inc · Expires 2031-03-29 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects unit dose formulations of a factor Xa inhibitor compound and methods of using it to inhibit blood coagulation in a human patient.

USPTO Abstract

Unit doses of factor Xa inhibitor compounds and methods of using these compounds for inhibiting blood coagulation in a human patient are taught herein. The unit dose of the factor Xa inhibitor compounds disclosed herein required to inhibit coagulation in a primate is lower than the unit dose required to obtain similar levels of coagulation inhibition in other animal models, such as rodents. Also taught are in vitro assays useful in predicting in vivo antithrombotic activity in humans.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2034 — Bevyxxa
U-2034 — Bevyxxa

Patent Metadata

Patent number
US8404724
Jurisdiction
US
Classification
Method of Use
Expires
2031-03-29
Drug substance claim
No
Drug product claim
Yes
Assignee
Millennium Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.